McKesson stock faces earnings test as analysts see profit growth
Published on 11/02/2026 at 12:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat investors await from McKesson
- McKesson is scheduled to report fiscal second-quarter 2027 results after the market close on Wednesday, November 4.
- Analysts expect quarterly diluted earnings per share to rise from the year-earlier period.
- Management is targeting adjusted fiscal 2027 earnings per share of 44.20 to 45.00 US dollars.
- The prior quarter combined revenue growth with an adjusted earnings beat.
McKesson is approaching its fiscal second-quarter 2027 report with profit growth in focus. The company is scheduled to release results after the U.S. market close on Wednesday, November 4, with its earnings call set for 4:30 p.m. Eastern Time, according to Yahoo Finance and Barchart.
Analysts cited in the preview expect diluted earnings of 10.69 US dollars per share for the quarter, up 8.4 percent from 9.86 US dollars a year earlier. The estimate sets a clear hurdle for the pharmaceutical distributor as investors assess whether recent earnings momentum can continue into the second half of its fiscal year.
Profit growth meets a higher bar
McKesson has exceeded Wall Street's EPS estimates in each of its last four quarterly reports, according to the preview. That record raises the importance of the November update: a result above consensus could reinforce the recent earnings narrative, while a smaller beat or weaker outlook could put more weight on the company's longer-term guidance.
The company expects adjusted fiscal 2027 earnings per share of 44.20 to 45.00 US dollars. Analysts expect full-year EPS of 44.71 US dollars, compared with 39.11 US dollars in fiscal 2026. The range and consensus will give investors a reference point for any change to management's outlook when the results are released.
McKesson entered the report period after a solid fiscal first quarter. On August 5, the company reported revenue of 105.4 billion US dollars and adjusted EPS of 9.93 US dollars, above the cited Wall Street estimates of 104.4 billion US dollars and 9.44 US dollars, respectively. The quarter's performance provides the latest operating benchmark for the upcoming release.
Stock trades ahead of results
McKesson stock traded at 885.00 euros on Lang & Schwarz at 12:38 CET on Monday, November 2. Investors can follow the real-time quote of McKesson stock.
McKesson Corporation
- ISIN: US58155Q1031
- Ticker: MCK
- Lang & Schwarz price: 885.00 euros at 12:38 CET on November 2, 2026
- Upcoming event: Fiscal second-quarter 2027 results on November 4, 2026, after the market close
The S&P 500 remains the relevant U.S. market backdrop for McKesson stock: Current market reports.
The November 4 release is the next scheduled catalyst for the investment case. Investors will focus on quarterly earnings, the development of the pharmaceutical distribution business and any adjustment to the 44.20-to-45.00-US-dollar adjusted EPS outlook. More news and analyses on McKesson stock.
